Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 4Ovarian Neoplasms 3Lung Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Mesothelioma, Malignant 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms, Mesothelial 1Multiple Myeloma 1Mesothelioma 1Mesonephric Gynecologic Cancer 1Melanoma 1Lymphoma 1Low-Grade Serous Ovarian Cancer 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Colorectal Cancer 1

Interventions

defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesonephric Gynecologic Cancer × defactinib × Clear all
NCT05787561 2026-04-28

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Gynecologic

Mesonephric Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡